Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024
Aytu BioPharma (Nasdaq: AYTU) has announced its participation in the upcoming Sidoti Micro-Cap Virtual Conference on August 14-15, 2024. The company's CEO, Josh Disbrow, will deliver a webcasted presentation on Thursday, August 15, at 12:15 p.m. Eastern time. This fireside chat will be accessible through Aytu's investor relations website and will remain available for replay after the event.
In addition to the presentation, Aytu's management team will engage in one-on-one meetings with investors throughout the conference. Interested parties can arrange meetings through their Sidoti representatives or by contacting Aytu's investor relations team directly. This event provides an opportunity for investors to gain insights into Aytu BioPharma, a pharmaceutical company focused on commercializing novel therapeutics.
Aytu BioPharma (Nasdaq: AYTU) ha annunciato la sua partecipazione alla prossima Sidoti Micro-Cap Virtual Conference che si terrà dal 14 al 15 agosto 2024. Il CEO dell'azienda, Josh Disbrow, terrà una presentazione in webcast giovedì 15 agosto alle 12:15 ora orientale. Questa chiacchierata informale sarà accessibile tramite il sito web delle relazioni con gli investitori di Aytu e rimarrà disponibile per la visione successiva all'evento.
Oltre alla presentazione, il team di gestione di Aytu svolgerà incontri individuali con gli investitori durante tutta la conferenza. Le parti interessate possono organizzare incontri tramite i loro rappresentanti Sidoti o contattando direttamente il team delle relazioni con gli investitori di Aytu. Questo evento offre un'opportunità agli investitori per acquisire informazioni su Aytu BioPharma, un'azienda farmaceutica focalizzata sulla commercializzazione di nuove terapie.
Aytu BioPharma (Nasdaq: AYTU) ha anunciado su participación en la próxima Sidoti Micro-Cap Virtual Conference que se llevará a cabo del 14 al 15 de agosto de 2024. El CEO de la compañía, Josh Disbrow, presentará una presentación por webcast el jueves 15 de agosto a las 12:15 p.m. hora del Este. Esta charla informal será accesible a través del sitio web de relaciones con inversores de Aytu y permanecerá disponible para su visualización posterior al evento.
Además de la presentación, el equipo de gestión de Aytu participará en reuniones individuales con inversores a lo largo de la conferencia. Las partes interesadas pueden organizar reuniones a través de sus representantes de Sidoti o contactando directamente al equipo de relaciones con inversores de Aytu. Este evento ofrece a los inversores la oportunidad de obtener información sobre Aytu BioPharma, una empresa farmacéutica centrada en la comercialización de terapias novedosas.
Aytu BioPharma (Nasdaq: AYTU)는 2024년 8월 14일부터 15일까지 열리는 Sidoti Micro-Cap Virtual Conference에 참여한다고 발표했습니다. 회사의 CEO인 Josh Disbrow는 8월 15일 목요일 오전 12시 15분 동부 표준시를 기준으로 웹캐스트 발표를 진행합니다. 이 대화는 Aytu의 투자자 관계 웹사이트를 통해 접근할 수 있으며, 행사 후에도 재생할 수 있습니다.
발표 외에도 Aytu의 관리 팀은 컨퍼런스 기간 동안 투자자와 개별 회의를 진행할 것입니다. 관심 있는 당사자는 Sidoti 대표를 통해 회의를 주선하거나 Aytu의 투자자 관계 팀에 직접 연락하여 회의를 조정할 수 있습니다. 이 행사는 투자자에게 혁신적인 치료제를 상용화하는 데 집중하는 제약 회사인 Aytu BioPharma에 대한 통찰을 얻을 수 있는 기회를 제공합니다.
Aytu BioPharma (Nasdaq: AYTU) a annoncé sa participation à la prochaine Sidoti Micro-Cap Virtual Conference qui se déroulera du 14 au 15 août 2024. Le PDG de l'entreprise, Josh Disbrow, fera une présentation en webcast le jeudi 15 août à 12h15, heure de l'Est. Ce chat informel sera accessible via le site web des relations avec les investisseurs d'Aytu et restera disponible en replay après l'événement.
En plus de la présentation, l'équipe de direction d'Aytu participera à des réunions individuelles avec des investisseurs tout au long de la conférence. Les parties intéressées peuvent organiser des réunions par l'intermédiaire de leurs représentants Sidoti ou en contactant directement l'équipe des relations avec les investisseurs d'Aytu. Cet événement offre une occasion aux investisseurs d'obtenir des informations sur Aytu BioPharma, une entreprise pharmaceutique axée sur la commercialisation de nouvelles thérapies.
Aytu BioPharma (Nasdaq: AYTU) hat seine Teilnahme an der bevorstehenden Sidoti Micro-Cap Virtual Conference am 14. und 15. August 2024 bekannt gegeben. Der CEO des Unternehmens, Josh Disbrow, wird am Donnerstag, den 15. August, um 12:15 Uhr Eastern Time eine Webcast-Präsentation halten. Dieses informelle Gespräch wird über die Website der Investor Relations von Aytu zugänglich sein und nach der Veranstaltung für eine Wiederholung verfügbar bleiben.
Zusätzlich zur Präsentation wird das Managementteam von Aytu während der gesamten Konferenz eins-zu-eins-Meetings mit Investoren führen. Interessierte Parteien können Meetings über ihre Sidoti-Vertreter oder direkt über das Investor-Relations-Team von Aytu arrangieren. Diese Veranstaltung bietet Investoren die Möglichkeit, Einblicke in Aytu BioPharma zu gewinnen, ein pharmazeutisches Unternehmen, das sich auf die Kommerzialisierung neuartiger Therapeutika konzentriert.
- None.
- None.
DENVER, CO / ACCESSWIRE / August 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq: AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will participate in a webcasted presentation and host one-on-one meetings with investors at the Sidoti Micro-Cap Virtual Conference, taking place virtually on Wednesday, August 14, 2024, and Thursday, August 15, 2024.
Webcast
The webcasted fireside chat will take place at 12:15 p.m. Eastern time on Thursday, August 15, 2024. The webcast can be accessed by visiting the investor relations section of the Company's website at https://investors.aytubio.com or directly here. The webcast will also be available for replay following the event.
1x1 Meetings
Management will also be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact your Sidoti representative or the Company's investor relations team at aytu@lythampartners.com.
About Aytu BioPharma, Inc.
Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.
Contacts for Investors
Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
moki@aytubio.com
Robert Blum or Roger Weiss
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on accesswire.com
FAQ
When is Aytu BioPharma (AYTU) participating in the Sidoti Micro-Cap Virtual Conference?
What time is Aytu BioPharma's (AYTU) webcasted presentation at the Sidoti conference?
How can investors access Aytu BioPharma's (AYTU) webcast at the Sidoti conference?
Will Aytu BioPharma (AYTU) be available for one-on-one meetings during the Sidoti conference?
How can investors arrange a meeting with Aytu BioPharma (AYTU) during the Sidoti conference?
